RT Journal Article
SR Electronic
T1 Reduced seroconversion in children compared to adults with mild COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.17.21265121
DO 10.1101/2021.10.17.21265121
A1 Zheng Quan Toh
A1 Jeremy Anderson
A1 Nadia Mazarakis
A1 Melanie Neeland
A1 Rachel A. Higgins
A1 Karin Rautenbacher
A1 Kate Dohle
A1 Jill Nguyen
A1 Isabella Overmars
A1 Celeste Donato
A1 Sohinee Sarkar
A1 Vanessa Clifford
A1 Andrew Daley
A1 Suellen Nicholson
A1 Francesca L. Mordant
A1 Kanta Subbarao
A1 David P. Burgner
A1 Nigel Curtis
A1 Julie E. Bines
A1 Sarah McNab
A1 Andrew C. Steer
A1 Kim Mulholland
A1 Shidan Tosif
A1 Nigel W. Crawford
A1 Daniel G. Pellicci
A1 Lien Anh Ha Do
A1 Paul V Licciardi
YR 2021
UL http://medrxiv.org/content/early/2021/10/18/2021.10.17.21265121.abstract
AB Importance The immune response in children with SARS-CoV-2 infection is not well understood.Objective To compare seroconversion in children and adults with non-hospitalized (mild) SARS-CoV-2 infection and to understand the factors that influence this.Design Participants were part of a household cohort study of SARS-CoV-2 infection. Weekly nasopharyngeal/throat swabs and blood samples were collected during the acute and convalescent period following PCR diagnosis for analysis.Setting Participants were recruited at the Royal Children’s Hospital, Melbourne, Australia between May and October 2020.Participants Those who had a SARS-CoV-2 PCR-positive nasal/throat swab.Main outcomes and measures SARS-CoV-2 antibody and cellular responses in children and adults. Seroconversion was defined by seropositivity in all three serological assays.Results Among 108 SARS-CoV-2 PCR-positive participants, 57 were children (median age: 4, IQR 2-10) and 51 were adults (median age: 37, IQR 34-45). Using three established serological assays, a lower proportion of children seroconverted compared with adults [20/54 (37.0%) vs 32/42 (76.2%); (p<0.001)]. This was not related to viral load, which was similar in children and adults [mean Ct 28.58 (SD: 6.83) vs 24.14 (SD: 8.47)]. Age and sex also did not influence seroconversion or the magnitude of antibody response within children or adults. Notably, in adults (but not children) symptomatic adults had three-fold higher antibody levels than asymptomatic adults (median 227.5 IU/mL, IQR 133.7-521.6 vs median 75.3 IU/mL, IQR 36.9-113.6). Evidence of cellular immunity was observed in adults who seroconverted but not in children who seroconverted.Conclusion and Relevance In this non-hospitalized cohort with mild COVID-19, children were less likely to seroconvert than adults despite similar viral loads. This has implications for future protection following COVID-19 infection in children and for interpretation of serosurveys that involve children. Further research to understand why children are less likely to seroconvert and develop symptoms following SARS-CoV-2 infection, and comparison with vaccine responses may be of clinical and scientific importance.Question What proportion of children with non-hospitalized (mild) SARS-CoV-2 infection seroconvert compared to adults?Findings In this cohort study conducted in 2020, we found the proportion of children who seroconverted to SARS-CoV-2 was half that in adults despite similar viral load.Meaning Serology is a less reliable marker of prior SARS-CoV-2 infection in children. SARS-CoV-2-infected children who do not seroconvert may be susceptible to reinfection. Our findings support strategies to protect children against COVID-19 including vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementRoyal Children's Hospital Foundation, Melbourne, Australia; Infection and Immunity Theme, Murdoch Children's Research InstituteAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Royal Childrens Hospital Human Research Ethics Committee gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript